𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Double blind comparative study of remoxipride and haloperidol in acute schizophrenic patients

✍ Scribed by J. A. Boer; D. P. Ravelli; J. Huisman; J. Ohrvik; W. M. A. Verhoeven; H. G. M. Westenberg

Publisher
Springer
Year
1990
Tongue
English
Weight
798 KB
Volume
102
Category
Article
ISSN
0033-3158

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

A double-blind comparative trial of remo
A double-blind comparative trial of remoxipride and haloperidol in the treatment of schizophrenia
✍ R. Deo; S. Soni; S. C. Rastogi; S. Levine; I. Plant; J. Guy Edwards; M. J. Mitch πŸ“‚ Article πŸ“… 1990 πŸ› John Wiley and Sons 🌐 English βš– 577 KB

A multicentre parallel group study was carried out to compare the efficacy and safety of remoxipride, a new antipsychotic drug, with haloperidol in the treatment of acute schizophrenia. Patients were randomly assigned to the two groups and assessments were made under double-blind conditions. Treatme

A randomized controlled double blind stu
A randomized controlled double blind study of zuclopenthixol acetate compared to haloperidol in acute psychosis
✍ S. Brook; M. Berk; S. Selemani; J. Kolloori; I. Nzo πŸ“‚ Article πŸ“… 1998 πŸ› John Wiley and Sons 🌐 English βš– 88 KB πŸ‘ 3 views

This study is a double blind randomized controlled trial comparing zuclopenthixol acetate to haloperidol administered parenterally initially and followed by oral medication for 28 days in the treatment of acute psychosis. The sample included 44 patients with schizophrenia, schizophreniform disorder

Double-blind study comparing doxercalcif
Double-blind study comparing doxercalciferol and placebo in vitamin D-replete CKD patients
✍ Anita Patel; John Robertson; Christine Darwin; Harold Locay; Ramon AΓ±el; Sara En πŸ“‚ Article πŸ“… 2011 πŸ› Wiley (John Wiley & Sons) 🌐 English βš– 91 KB

OBJECTIVE: No well-controlled studies of the safety and effi cacy of active vitamin D analogues have been conducted in vitamin D-replete (25-hydroxyvitamin D Υ† 30 ng/mL) patients. This study assessed the safety and effi cacy of doxercalciferol in vitamin D-replete patients with secondary hyperparath